

Letter to the Editor: NMR assignment of the SH2 domain from the human feline sarcoma oncogene FES

Anna Scott^{a,**}, David Pantoja-Uceda^a, Seizo Koshiba^b, Makoto Inoue^b, Takanori Kigawa^b, Takaho Terada^{b,c}, Mikako Shirouzu^{b,c}, Akiko Tanaka^b, Sumio Sugano^d, Shigeyuki Yokoyama^{b,c,e} & Peter Güntert^{a,*}

^aTatsuo Miyazawa Memorial Program, RIKEN Genomic Sciences Center, 1-7-22, Suehiro-cho, Tsurumi, Yokohama 230-0045, Japan; ^bRIKEN Genomic Sciences Center, 1-7-22, Suehiro-cho, Tsurumi, Yokohama 230-0045, Japan; ^cRIKEN Harima Institute at SPring-8, 1-1-1 Kouto, Mikazuki, Sayo, Hyogo 679-5148, Japan; ^dDepartment of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; ^eDepartment of Biophysics and Biochemistry, Graduate School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan

Received 4 October 2004; Accepted 21 October 2004

Key words: feline sarcoma oncogene, FES, NMR assignment, SH2 domain, structural genomics

Biological context

The human FES (feline sarcoma oncogene) protein is one of two members of a family of non-receptor tyrosine kinases. FES was originally isolated as a retroviral oncogene in avian and feline retroviruses. Genetic analysis identified its cellular homologs, *fes/fps*. The function of FES is still not fully understood. However, it is known to be involved in the growth and differentiation of myeloid hematopoietic cells, vascular endothelial cells and neurons. It is also implicated in the regulation of cytoskeletal rearrangement (Greer, 2002; Takashima et al., 2003).

FES contains multiple domains: Fps/Fes/Fer/CIP4 homology, Src homology 2 (SH2), coiled coil, and tyrosine kinase. Of particular interest is the SH2 domain (residues 450–550), which is implicated in maintaining FES in an inactive state (Takashima et al., 2003).

Methods and experiments

The human FES SH2 domain was produced as a 147-amino-acid recombinant protein with an

N-terminal HAT affinity tag and a TEV protease cleavage site. The ¹³C- and ¹⁵N-labeled protein was produced by the *E. coli* cell-free synthesis system (Kigawa et al., 1999). The protein was first adsorbed to a HisTrap HP affinity column (Amersham Biosciences) using 20 mM Tris-HCl (pH 8.0) containing 1 M NaCl and 12 mM imidazole, and eluted with 20 mM Tris-HCl (pH 8.0) containing 500 mM NaCl and 500 mM imidazole. After exchange of buffer to 20 mM Tris-HCl (pH 8.0) containing 1 M NaCl and 15 mM imidazole, the HAT-tag was removed by incubation with the TEV protease at 30 °C for 1 h. To remove the HAT-tag and TEV protease from the reaction mixture, the solution was applied to a HisTrap HP affinity column. The flowthrough fraction was desalted and loaded onto a HiTrap SP column (Amersham Biosciences) equilibrated with 20 mM Tris-HCl (pH 8.0) containing 1 mM EDTA. The flowthrough fraction was applied to a HiTrap Q anion exchange column (Amersham Biosciences) equilibrated with 20 mM Tris-HCl (pH 8.5) containing 1 mM EDTA. Finally, the purified protein was eluted with a gradient of 0–1 M NaCl.

The protein sample used for the NMR measurements comprises 114 amino acid residues. Residues 8–108 constitute the SH2 domain which is surrounded by non-native flanking sequences of residues 1–7 and 109–114 that are related to

*To whom correspondence should be addressed. E-mail: guentert@gsc.riken.jp

**Present address: University of Utah, Department of Biochemistry, Salt Lake City UT 84103-3201, U.S.A.

